Article Text

other Versions

PDF
The effects of donepezil on nicotinic receptor status in dementia: A 123I-5IA-85380 SPECT study
  1. S J Colloby (s.j.colloby{at}ncl.ac.uk)
  1. University of Newcastle upon Tyne, United Kingdom
    1. S Pakrasi (sanjeet.pakrasi{at}ncl.ac.uk)
    1. Newcastle University, United Kingdom
      1. E K Perry (e.k.perry{at}ncl.ac.uk)
      1. Newcastle General Hospital, United Kingdom
        1. S L Pimlott (gcl515{at}clinmed.gla.ac.uk)
        1. Western Infimary, Glasgow, United Kingdom
          1. D J Wyper (d.wyper{at}udcf.gla.ac.uk)
          1. Southern General Hospital, United Kingdom
            1. E D Williams (david.williams{at}chs.northy.nhs.uk)
            1. Sunderland Royal Infirmary, United Kingdom
              1. I G McKeith (i.g.mckeith{at}ncl.ac.uk)
              1. University of Newcastle, United Kingdom
                1. J T O’Brien (j.t.o'brien{at}ncl.ac.uk)
                1. University of Newcastle upon Tyne, United Kingdom

                  Abstract

                  Disturbances in the cerebral cholinergic nervous system and subsequent reduction of acetylcholine (ACh) are neurochemical features of AD and DLB, and treatments with acetylcholinesterase inhibitors (AChEIs) offer symptomatic improvement in cognitive and non-cognitive symptoms. One important subclass of acetylcholine receptors are nicotinic acetylcholine receptors (nAChR), and have been shown to be implicated in memory and cognitive processes.

                  • Dementia
                  • Donepezil
                  • SPECT
                  • SPM

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.